Drilldown: Medicines

None (1) · Nebivolol (1) · Norethindrone (norethisterone outside US) (1) · Tadalafil (1)

Aimovig (1) · Aygestin (5 mg, Rx); Camila, Errin, Heather, Jolivette, Nor-QD, Ortho Micronor, Sharobel (0.35 mg POPs); component of many COCs (1) · Bystolic (1) · Cialis, Adcirca (1)

Anti-CGRP receptor monoclonal antibody (1) · Beta Blocker (1) · Cardioselective (β1) + vasodilator (1) · PDE5 Inhibitor (1) · [[:Category:Hormonal_contraceptives|Hormonal contraceptive]] (1) · [[:Category:Progestins|Progestin (synthetic progestogen)]] (1) · [[:Category:Sex_hormones|Sex hormone]] (1)

Humanized IgG2 monoclonal antibody binding the CGRP receptor (not the peptide); blocks CGRP-mediated vasodilation and nociceptive signaling (1) · Selective inhibitor of PDE5 with a substantially longer half-life than other PDE5 inhibitors, allowing once-daily continuous dosing. (1) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) · '"`UNIQ--vote-000013EE-QINU`"' Higher-dose Aygestin (5 mg) achieves more reliable ovulation suppression and is used for endometriosis and DUB. POP requires strict daily timing because the 24-hour cervical-mucus effect window is narrower than COC'"`UNIQ--ref-000013EF-QINU`"'. (1)

Preventive treatment of migraine in adults (episodic and chronic) (1) · '"`UNIQ--vote-0000059D-QINU`"' (1) · '"`UNIQ--vote-00000738-QINU`"', '"`UNIQ--vote-00000739-QINU`"', '"`UNIQ--vote-0000073A-QINU`"' (1) · '"`UNIQ--vote-000013F0-QINU`"', '"`UNIQ--vote-000013F1-QINU`"', '"`UNIQ--vote-000013F2-QINU`"', '"`UNIQ--vote-000013F3-QINU`"', '"`UNIQ--vote-000013F4-QINU`"' (1)

10 mg PRN; 2.5–5 mg daily for continuous coverage / BPH (1) · 5 mg daily (1) · 70 mg SC monthly; may increase to 140 mg monthly (1) · POP: 0.35 mg PO daily continuously (no placebo week); high-dose 5 mg Aygestin for amenorrhea/endometriosis 5-10 mg/d (1)

None · 10 mg, 20 mg, 40 mg, 80 mg tablets · 2.5, 5, 10, 20 mg tabs · 5 mg, 10 mg tablets · 5, 10 mg tablets · 5, 10, 20, 40 mg tablets · 0.005% ophthalmic solution (50 mcg/mL); typical 2.5 mL bottle · 0.01%, 0.03% ophthalmic solution · 0.025%, 0.035% ophthalmic solutions · 0.1% (Patanol), 0.2% (Pataday once-daily original), 0.7% (Pataday 24-hour) ophthalmic solutions; 0.6% nasal spray · 0.1%, 0.15% intranasal spray; 0.05% ophthalmic solution; combination Dymista (azelastine 0.137 mg + fluticasone 50 mcg/spray) · 0.1%, 0.15%, 0.2% ophthalmic solutions; 0.33% topical gel; combinations with timolol (Combigan) and brinzolamide (Simbrinza) · 0.225%, 0.45%, 0.9%, 3%, 5% IV solutions; 0.9% nasal spray; 3% and 7% nebulizer solutions; oral tablets (1 g) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate · 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets · 0.25, 0.5 mcg oral capsules; 1 mcg/mL oral solution; 1 mcg/mL IV; 3 mcg/g topical ointment · 0.35 mg POP tablets; 5 mg tablets (Aygestin); component of COCs and combination HRT · 0.4 mg capsules · 0.4, 0.8, 1 mg OTC; 1 mg Rx; 5 mg/mL injection · 0.5 g, 1 g capsules

Other values:

Search

140 mg/month (1) · 20 mg/d (ED, PRN); 5 mg/d (daily / BPH); 40 mg/d (PAH) (1) · 40 mg/d (1) · Indication-specific (1)

Oral (3) · Subcutaneous (1)

1–2 h (1) · 30 min (1) · Contraception within 48 hours of starting (POP); endometrial effects days (1) · Onset of preventive effect over weeks; some patients respond after first dose (1)

24 h (1) · Monthly dosing (1) · Up to 36 h ("the weekend pill") (1) · ~24 hours per dose (strict timing required for POP — within 3-hour window each day) (1)

~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~17.5 h (1) · ~28 days (1) · ~8 hours'"`UNIQ--ref-000013F5-QINU`"' (1)

Reasonable (not formally established as a percentage) (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~65% (oral)'"`UNIQ--ref-000013F6-QINU`"' (1) · ~82% SC (1)

Category B (1) · Category C (1) · Contraindicated in known pregnancy (Aygestin); the 0.35 mg POP is not teratogenic and does not need to be discontinued before conception planning.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data; avoid (1)

Rx (1) · Rx-only in US (2) · [[USLegal:Prescription only|Rx-only]] in US (note: norgestrel 0.075 mg POP is now OTC as Opill since 2023, but norethindrone POP remains Rx) (1)